Japanese Dermatological Association Guidelines: Guidelines for the treatment of acne vulgaris 2017

Nobukazu Hayashi, Hirohiko Akamatsu, Keiji Iwatsuki, Ryoko Shimada-Omori, Chikako Kaminaka, Ichiro Kurokawa, Takeshi Kono, Miwa Kobayashi, Miki Tanioka, Fukumi Furukawa, Minao Furumura, Osamu Yamasaki, Kenshi Yamasaki, Yuki Yamamoto, Yoshiki Miyachi, Makoto Kawashima

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The Guidelines for the Treatment of Acne Vulgaris of the Japanese Dermatological Association was first published in Japanese in 2008 and revised in 2016 and 2017. These guidelines (GL) indicate the standard acne treatments in Japan and address pharmaceutical drugs and treatments applicable or in use in Japan. In these GL, the strength of the recommendation is based on clinical evidences as well as availability in Japanese medical institutions. In the 2016 and 2017 GL, some of the clinical questions were revised, and other questions were added in accordance with approval of topical medicines containing benzoyl peroxide (BPO). Rather than monotherapies of antibiotics, the 2017 GL more strongly recommend combination therapies, especially fixed-dose combination gels including BPO in the aspects of pharmacological actions and compliance in the acute inflammatory phase to achieve earlier and better improvements. The 2017 GL also indicate to limit the antimicrobial treatments for the acute inflammatory phase up to approximately 3 months and recommend BPO, adapalene, and a fixed-dose combination gel of 0.1% adapalene and 2.5% BPO for the maintenance phase to avoid the emergence of antimicrobial-resistant Propionibacterium acnes. The 2017 GL also discuss rosacea, which requires discrimination from acne and a different treatment plan.

Original languageEnglish
JournalJournal of Dermatology
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Acne Vulgaris
Benzoyl Peroxide
Guidelines
Japan
Gels
Rosacea
Propionibacterium acnes
Pharmaceutical Preparations
Compliance
Maintenance
Pharmacology
Anti-Bacterial Agents

Keywords

  • Acne vulgaris
  • Antimicrobial resistant
  • Guideline
  • Maintenance therapy
  • Propionibacterium acnes

ASJC Scopus subject areas

  • Dermatology

Cite this

Hayashi, N., Akamatsu, H., Iwatsuki, K., Shimada-Omori, R., Kaminaka, C., Kurokawa, I., ... Kawashima, M. (Accepted/In press). Japanese Dermatological Association Guidelines: Guidelines for the treatment of acne vulgaris 2017. Journal of Dermatology. https://doi.org/10.1111/1346-8138.14355

Japanese Dermatological Association Guidelines : Guidelines for the treatment of acne vulgaris 2017. / Hayashi, Nobukazu; Akamatsu, Hirohiko; Iwatsuki, Keiji; Shimada-Omori, Ryoko; Kaminaka, Chikako; Kurokawa, Ichiro; Kono, Takeshi; Kobayashi, Miwa; Tanioka, Miki; Furukawa, Fukumi; Furumura, Minao; Yamasaki, Osamu; Yamasaki, Kenshi; Yamamoto, Yuki; Miyachi, Yoshiki; Kawashima, Makoto.

In: Journal of Dermatology, 01.01.2018.

Research output: Contribution to journalArticle

Hayashi, N, Akamatsu, H, Iwatsuki, K, Shimada-Omori, R, Kaminaka, C, Kurokawa, I, Kono, T, Kobayashi, M, Tanioka, M, Furukawa, F, Furumura, M, Yamasaki, O, Yamasaki, K, Yamamoto, Y, Miyachi, Y & Kawashima, M 2018, 'Japanese Dermatological Association Guidelines: Guidelines for the treatment of acne vulgaris 2017', Journal of Dermatology. https://doi.org/10.1111/1346-8138.14355
Hayashi, Nobukazu ; Akamatsu, Hirohiko ; Iwatsuki, Keiji ; Shimada-Omori, Ryoko ; Kaminaka, Chikako ; Kurokawa, Ichiro ; Kono, Takeshi ; Kobayashi, Miwa ; Tanioka, Miki ; Furukawa, Fukumi ; Furumura, Minao ; Yamasaki, Osamu ; Yamasaki, Kenshi ; Yamamoto, Yuki ; Miyachi, Yoshiki ; Kawashima, Makoto. / Japanese Dermatological Association Guidelines : Guidelines for the treatment of acne vulgaris 2017. In: Journal of Dermatology. 2018.
@article{add9f10656e64c4aae5a77348bcdd1d6,
title = "Japanese Dermatological Association Guidelines: Guidelines for the treatment of acne vulgaris 2017",
abstract = "The Guidelines for the Treatment of Acne Vulgaris of the Japanese Dermatological Association was first published in Japanese in 2008 and revised in 2016 and 2017. These guidelines (GL) indicate the standard acne treatments in Japan and address pharmaceutical drugs and treatments applicable or in use in Japan. In these GL, the strength of the recommendation is based on clinical evidences as well as availability in Japanese medical institutions. In the 2016 and 2017 GL, some of the clinical questions were revised, and other questions were added in accordance with approval of topical medicines containing benzoyl peroxide (BPO). Rather than monotherapies of antibiotics, the 2017 GL more strongly recommend combination therapies, especially fixed-dose combination gels including BPO in the aspects of pharmacological actions and compliance in the acute inflammatory phase to achieve earlier and better improvements. The 2017 GL also indicate to limit the antimicrobial treatments for the acute inflammatory phase up to approximately 3 months and recommend BPO, adapalene, and a fixed-dose combination gel of 0.1{\%} adapalene and 2.5{\%} BPO for the maintenance phase to avoid the emergence of antimicrobial-resistant Propionibacterium acnes. The 2017 GL also discuss rosacea, which requires discrimination from acne and a different treatment plan.",
keywords = "Acne vulgaris, Antimicrobial resistant, Guideline, Maintenance therapy, Propionibacterium acnes",
author = "Nobukazu Hayashi and Hirohiko Akamatsu and Keiji Iwatsuki and Ryoko Shimada-Omori and Chikako Kaminaka and Ichiro Kurokawa and Takeshi Kono and Miwa Kobayashi and Miki Tanioka and Fukumi Furukawa and Minao Furumura and Osamu Yamasaki and Kenshi Yamasaki and Yuki Yamamoto and Yoshiki Miyachi and Makoto Kawashima",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/1346-8138.14355",
language = "English",
journal = "Journal of Dermatology",
issn = "0385-2407",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Japanese Dermatological Association Guidelines

T2 - Guidelines for the treatment of acne vulgaris 2017

AU - Hayashi, Nobukazu

AU - Akamatsu, Hirohiko

AU - Iwatsuki, Keiji

AU - Shimada-Omori, Ryoko

AU - Kaminaka, Chikako

AU - Kurokawa, Ichiro

AU - Kono, Takeshi

AU - Kobayashi, Miwa

AU - Tanioka, Miki

AU - Furukawa, Fukumi

AU - Furumura, Minao

AU - Yamasaki, Osamu

AU - Yamasaki, Kenshi

AU - Yamamoto, Yuki

AU - Miyachi, Yoshiki

AU - Kawashima, Makoto

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The Guidelines for the Treatment of Acne Vulgaris of the Japanese Dermatological Association was first published in Japanese in 2008 and revised in 2016 and 2017. These guidelines (GL) indicate the standard acne treatments in Japan and address pharmaceutical drugs and treatments applicable or in use in Japan. In these GL, the strength of the recommendation is based on clinical evidences as well as availability in Japanese medical institutions. In the 2016 and 2017 GL, some of the clinical questions were revised, and other questions were added in accordance with approval of topical medicines containing benzoyl peroxide (BPO). Rather than monotherapies of antibiotics, the 2017 GL more strongly recommend combination therapies, especially fixed-dose combination gels including BPO in the aspects of pharmacological actions and compliance in the acute inflammatory phase to achieve earlier and better improvements. The 2017 GL also indicate to limit the antimicrobial treatments for the acute inflammatory phase up to approximately 3 months and recommend BPO, adapalene, and a fixed-dose combination gel of 0.1% adapalene and 2.5% BPO for the maintenance phase to avoid the emergence of antimicrobial-resistant Propionibacterium acnes. The 2017 GL also discuss rosacea, which requires discrimination from acne and a different treatment plan.

AB - The Guidelines for the Treatment of Acne Vulgaris of the Japanese Dermatological Association was first published in Japanese in 2008 and revised in 2016 and 2017. These guidelines (GL) indicate the standard acne treatments in Japan and address pharmaceutical drugs and treatments applicable or in use in Japan. In these GL, the strength of the recommendation is based on clinical evidences as well as availability in Japanese medical institutions. In the 2016 and 2017 GL, some of the clinical questions were revised, and other questions were added in accordance with approval of topical medicines containing benzoyl peroxide (BPO). Rather than monotherapies of antibiotics, the 2017 GL more strongly recommend combination therapies, especially fixed-dose combination gels including BPO in the aspects of pharmacological actions and compliance in the acute inflammatory phase to achieve earlier and better improvements. The 2017 GL also indicate to limit the antimicrobial treatments for the acute inflammatory phase up to approximately 3 months and recommend BPO, adapalene, and a fixed-dose combination gel of 0.1% adapalene and 2.5% BPO for the maintenance phase to avoid the emergence of antimicrobial-resistant Propionibacterium acnes. The 2017 GL also discuss rosacea, which requires discrimination from acne and a different treatment plan.

KW - Acne vulgaris

KW - Antimicrobial resistant

KW - Guideline

KW - Maintenance therapy

KW - Propionibacterium acnes

UR - http://www.scopus.com/inward/record.url?scp=85047479131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047479131&partnerID=8YFLogxK

U2 - 10.1111/1346-8138.14355

DO - 10.1111/1346-8138.14355

M3 - Article

C2 - 29782039

AN - SCOPUS:85047479131

JO - Journal of Dermatology

JF - Journal of Dermatology

SN - 0385-2407

ER -